Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind I…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
Cantargia AB (FRA:7V3) (Q2 2026) Earnings Call Highlights: Strong Cash Position and Promising ... Company reports complete remission in all evaluable high-risk MDS patients and secures funding to extend runway into mid-2028. | ||
Older | ||
Cantargia AB (FRA:7V3) Q4 2025 Earnings Call Highlights: A Year of First-Time Profitability ... Cantargia AB (FRA:7V3) celebrates its first profitable year with SEK316.7 million in revenue, while navigating financial and regulatory hurdles. | ||
Cantargia AB (FRA:7V3) Q3 2025 Earnings Call Highlights: First-Ever Profits and Promising ... Cantargia AB (FRA:7V3) reports its inaugural revenues and profits, driven by a lucrative Otsuka deal, while showcasing promising advancements in cancer treatment. | ||
Cantargia AB (STU:7V3) Q2 2025 Earnings Call Highlights: Strategic Moves and Financial Updates Cantargia AB (STU:7V3) secures a major deal with Otsuka, reports financial flexibility, and anticipates first revenue recognition. | ||